BIOXCEL THERA (BTAI)

The momentum for this stock is not very good. BIOXCEL THERA (BTAI) is not very popular among insiders. Tradey thinks it is not wise to invest in BIOXCEL THERA (BTAI).
Log in to see more information.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development...
BTAI Fundamental Data by TradingView

News

HC Wainwright Reiterates "Buy" Rating for BioXcel Therapeutics (NASDAQ:BTAI)
HC Wainwright Reiterates "Buy" Rating for BioXcel Therapeutics (NASDAQ:BTAI)

Ticker Report HC Wainwright restated their buy rating on shares of BioXcel Therapeutics (NASDAQ:BTAI - Free Report) in a research note published on Friday, Benzinga reports. They currently have a $7.00 price...\n more…

BioXcel Therapeutics announces initiation of SERENITY Phase 3 trial
BioXcel Therapeutics announces initiation of SERENITY Phase 3 trial

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Globe Newswire Estimated 23 million annual agitation episodes in the at-home setting 1-3 No FDA-approved therapies in the at-home setting for acute treatment of agitation associated with bipolar disorders or...\n more…

BioXcel Therapeutics (NASDAQ:BTAI) Rating Reiterated by Canaccord Genuity Group
BioXcel Therapeutics (NASDAQ:BTAI) Rating Reiterated by Canaccord Genuity Group

Ticker Report BioXcel Therapeutics (NASDAQ:BTAI - Get Free Report)s stock had its "buy" rating reissued by equities researchers at Canaccord Genuity Group in a report issued on Friday, Benzinga reports...\n more…

BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks Investment Research The price trend for BioXcel Therapeutics, Inc. (BTAI) has been bearish lately and the stock has lost 6.6% over the past two weeks. However, the formation of a hammer chart pattern in its last trading...\n more…

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $5.50 Consensus Price Target from Brokerages
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $5.50 Consensus Price Target from Brokerages

Zolmax Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) have earned an average rating of "Moderate Buy" from the five ratings firms that are covering the stock, Marketbeat.com reports...\n more…